weight loss market studies

Semaglutide Boom – The Beginning of a Decline? New FDA Report

January 4, 2024 The history of weight loss drugs in the U.S. is filled with meds that were taken off the market due to nasty side effects, going back to the phen/fen crisis of 1997. Many more followed (Belviq, Qsymia, Taranabant, Acomplia) . These side effects did not emerge until years after entering the market […]

More Obesity Drugs in the Pipeline – Boehringer Ingelheim

News / John LaRosa

August 20, 2023 Boehringer Ingelheim could soon stake a claim in the lucrative obesity treatment market after the pharma company said it has advanced a candidate into three Phase III trials following promising data. Servodutide, the company’s glucagon/glucagon-like peptide 1 (GLP-1) receptor dual agonist co-developed with Zeland Pharma, demonstrated up to 19% weight loss after

More Obesity Drugs in the Pipeline – Boehringer Ingelheim Read More »

(813) 971-8080

Semaglutide Boom – The Beginning of a Decline? New FDA Report

More Obesity Drugs in the Pipeline – Boehringer Ingelheim